| Primary information |
|---|
| ID | 11490 |
| Uniprot ID | P61278 |
| Description | Somatostatin precursor (Growth hormone release-inhibiting factor)[Cleaved into- - Somatostatin-28; Somatostatin-14]. |
| Organism | Homo sapiens |
| Txonomy | Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata (jawed vertebrates); Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Boreoeutheria; Euarchontoglires; Primates; Haplorrhini; Simiiformes; Catarrhini; Hominoidea (apes); Hominidae (great apes); Homininae; Homo; Homo sapiens (Human) |
| Subcellular Location | Secreted |
| Developmental Stage | NA |
| Similarity | Belongs to the somatostatin family. |
| Tissue Specificity | NA |
| Post Translational Modification | NA |
| Function | Somatostatin inhibits the release of somatotropin |
| Length | 116 |
| Molecular Weight | 12736 |
| Name | Somatostatin-14 |
| Sequence | AGCKNFFWKTFTSC |
| Sequence map | 14 (103-116) |
| PDB ID | 1P2W |
| Drugpedia | NA |
| Receptor | P30872; P30874; P32745; P31391; P35346; P30872; P30874; P32745; P31391; P35346; P30872; P30874; P327 |
| Domain | NA |
| Pharmaceutical Use | A synthetic analog known as octreotide or SMS 201-995 is available under the name Sandostatin (Novartis). It is used for the treatment of a variety of disorders including acromegaly and the symptomati |